Eperisone
- (RS )-4' -ethyl -2-methyl -3- piperidinopropiophenone (IUPAC)
- Eperisonum (Latin )
- C17H25NO ( eperisone )
- C17H25NO · HCl ( eperisone · hydrochloride)
- 64840-90-0 ( eperisone )
- 56839-43-1 ( eperisone · hydrochloride)
M03BX09
· Eperisone hydrochloride is a white crystalline powder
Muscle relaxants
167 ° C ( eperisone · hydrochloride) (decomposition)
Slightly soluble in water, methanol and acetic acid; soluble in ethanol ( eperisone · hydrochloride)
129 mg · kg -1 ( LD50, mouse, i.p. hydrochloride)
Template: Infobox chemical / molecular formula search available
Eperisone is a drug from the group of anticonvulsants. He is not (yet) approved for the treatment unlike his relatives Tolperison in Europe. Eperisone but especially in many Asian countries, including China, India, Indonesia and Japan, used for the treatment of muscular tension, lumbago and spastic paralysis.
- 2.1 Areas of application
- 2.2 Side Effects
Pharmacology
Mode of action ( pharmacodynamics )
Eperisone is a centrally acting muscle relaxant drug. In addition, he has an analgesic action component. These effects are brought at the molecular level with a local anesthetic -like inhibition of voltage-gated sodium and calcium channels on primary afferent motor neurons and, thus, in conjunction with an inhibition of the release of transmitters in communication.
Clinical information
Areas of application
Eperisone is not yet approved in Europe and North America to therapy. One possible application for the treatment of spastic paralysis, spondylosis and back pain was evaluated in small clinical trials. The results of these clinical studies were interpreted by the authors as an indication of efficacy.
Side effects
During clinical trials, especially drowsiness, dizziness, loss of balance, nausea, vomiting and abdominal pain could be observed as an adverse drug side effects that may be in a possible association with the use of eperisone.
Trade names and dosage forms
Eperisone is marketed in Asia under the brand name Myonal.